BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA 2018;319:2486-96. [PMID: 29946728 DOI: 10.1001/jama.2018.7855] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Shen L, Li Q, Wang W, Zhu L, Zhao Q, Nie Y, Zhu B, Ma D, Lin X, Cai X, Fang W, Peng C, Chen Y, Fang H, Yin Z, Li H, Wang N, Xu R. Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China. J Med Econ 2020;23:456-63. [PMID: 31950863 DOI: 10.1080/13696998.2020.1717500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, Hu H, Weng S, Ding K, Yuan Y. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biol Ther 2019;20:391-6. [PMID: 30307354 DOI: 10.1080/15384047.2018.1529120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Wu Y, Fan Y, Dong D, Dong X, Hu Y, Shi Y, Jing J, Li E. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review. Ther Adv Med Oncol 2020;12:1758835920940932. [PMID: 32728393 DOI: 10.1177/1758835920940932] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Song Y, Qu T, Zhang H, Sun Y, Cui C, Chi Y, Zhang W, Wang X, Yang L. The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer. Cancer Manag Res 2021;13:6199-205. [PMID: 34393513 DOI: 10.2147/CMAR.S313275] [Reference Citation Analysis]
5 Peng Z, Hou X, Huang Y, Xie T, Hua X. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China. BMC Cancer 2020;20:990. [PMID: 33050905 DOI: 10.1186/s12885-020-07486-w] [Reference Citation Analysis]
6 Li J, Cong L, Liu J, Peng L, Wang J, Feng A, Yue J, Li L, Wang X, Wang X. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. Front Oncol 2020;10:594125. [PMID: 33282742 DOI: 10.3389/fonc.2020.594125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yu W, Tao Q, Zhang Y, Yi F, Feng L. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. J Oncol 2021;2021:9959946. [PMID: 34603452 DOI: 10.1155/2021/9959946] [Reference Citation Analysis]
8 Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390 [PMID: 34040699 DOI: 10.4251/wjgo.v13.i5.366] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Huang M, Yang Y, Zhu X, Chen Z, Zhang W, Wang C, Zhang X, Qiu L, Zhang Z, Zhao X, Li W, Wang Y, Guo W. A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. Asia Pac J Clin Oncol 2021. [PMID: 33567129 DOI: 10.1111/ajco.13511] [Reference Citation Analysis]
10 Sun L, Huang S, Li D, Mao Y, Wang Y, Wu J. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. Front Oncol 2021;11:754881. [PMID: 34692541 DOI: 10.3389/fonc.2021.754881] [Reference Citation Analysis]
11 Stefani C, Miricescu D, Stanescu-Spinu II, Nica RI, Greabu M, Totan AR, Jinga M. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now? Int J Mol Sci 2021;22:10260. [PMID: 34638601 DOI: 10.3390/ijms221910260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li N, Deng W, Zhang G, Du Y, Guo Y, Ma Y, Wei C, Bie L, Zhang C, Song T, Luo S, Fang B. Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. Front Oncol 2021;11:728854. [PMID: 34540697 DOI: 10.3389/fonc.2021.728854] [Reference Citation Analysis]
13 Ren C, Xu RH. The drug treatment research of gastrointestinal cancer in China. Eur J Surg Oncol 2020;46:e3-6. [PMID: 32591201 DOI: 10.1016/j.ejso.2020.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Liang X, Shen J. Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis. Journal of Chemotherapy 2020;32:41-8. [DOI: 10.1080/1120009x.2019.1692282] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Wang N, Zhang B, Zhang Q, Su W, Guo X, Li J. Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. Onco Targets Ther 2021;14:4439-50. [PMID: 34408440 DOI: 10.2147/OTT.S307273] [Reference Citation Analysis]
16 Zhang Q, Deng T, Yang F, Guo W, Liu D, Yuan J, Qi C, Cao Y, Yu Q, Cai H, Peng Z, Wang X, Zhou J, Lu M, Gong J, Li J, Ba Y, Shen L. A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor. Front Pharmacol 2022;13:833583. [DOI: 10.3389/fphar.2022.833583] [Reference Citation Analysis]
17 Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X, Zhou A, Zhang Z, Li G, Cai S, Xu R, Li J, Zhang S. Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. Chin J Cancer Res 2019;31:423-5. [PMID: 31354210 DOI: 10.21147/j.issn.1000-9604.2019.03.03] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
18 Chen Y, Xu YY, Jiang HJ, Wang L, Zhai JW, Zhang T, Yang YF. Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction. Chin J Integr Med 2022. [PMID: 35508862 DOI: 10.1007/s11655-022-3676-7] [Reference Citation Analysis]
19 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 65.0] [Reference Citation Analysis]
20 Liao X, Li H, Liu Z, Liao S, Li Q, Liang C, Huang Y, Xie M, Wei J, Li Y. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment. Medicine (Baltimore) 2018;97:e13635. [PMID: 30558053 DOI: 10.1097/MD.0000000000013635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tabernero J, Taieb J, Prager GW, Ciardiello F, Fakih M, Leger C, Fougeray R, Amellal N, van Cutsem E. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncol 2021;17:1977-85. [PMID: 33569986 DOI: 10.2217/fon-2020-1238] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang PF, Xie D, Li Q. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer. Tumori 2020;106:400-5. [PMID: 32354261 DOI: 10.1177/0300891620916789] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Shirley M. Fruquintinib: First Global Approval. Drugs 2018;78:1757-61. [PMID: 30357594 DOI: 10.1007/s40265-018-0998-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
24 Lu S, Chen G, Sun Y, Sun S, Chang J, Yao Y, Chen Z, Ye F, Lu J, Shi J, He J, Liu X, Zhang Y, Liu Z, Fang J, Cheng Y, Hu C, Mao W, Hu Y, Gong Y, Shan L, Yang Z, Song Y, Li W, Bai C, Wang B, Ma R, Zheng Z, Liu M, Jie Z, Cao L, Liao W, Pan H, Huang D, Chen Y, Yang J, Qin S, Ma S, Liang L, Liu Z, Zhou J, Tao M, Huang Y, Qiu F, Huang Y, Guan S, Peng M, Su W. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study. Lung Cancer 2020;146:252-62. [PMID: 32592986 DOI: 10.1016/j.lungcan.2020.06.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Zhang Y, Zou JY, Xu YY, He JN. Fruquintinib beneficial in elderly patient with neoplastic pericardial effusion from rectal cancer: A case report. World J Clin Cases 2021; 9(21): 6170-6177 [PMID: 34368339 DOI: 10.12998/wjcc.v9.i21.6170] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Xu J, Fan J, Qin X, Cai J, Gu J, Wang S, Wang X, Zhang S, Zhang Z; China CRLM Guideline Group. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). J Cancer Res Clin Oncol. 2019;145:725-736. [PMID: 30542791 DOI: 10.1007/s00432-018-2795-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
27 Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019;11:7787-7803. [PMID: 31496821 DOI: 10.2147/cmar.s215533] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
28 Guan X, Li H, Xiong X, Peng C, Wang N, Ma X, Ma A. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. J Med Econ 2021;24:339-44. [PMID: 33571036 DOI: 10.1080/13696998.2021.1888743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kang XL, He LR, Chen YL, Wang SB. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis. World J Gastroenterol 2020; 26(43): 6853-6866 [PMID: 33268966 DOI: 10.3748/wjg.v26.i43.6853] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
30 Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, Lin P, Cai X, Han X, Zhao F, Shu Y, Chang L, Jiang H, Gu Y. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. Oncologist 2019;24:883-e407. [PMID: 30877190 DOI: 10.1634/theoncologist.2019-0164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
31 Li Q, Cheng X, Zhou C, Tang Y, Li F, Zhang B, Huang T, Wang J, Tu S. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer. Front Oncol 2022;12:841977. [DOI: 10.3389/fonc.2022.841977] [Reference Citation Analysis]
32 Fernández-Montes A, Grávalos C, Pericay C, Safont MJ, Benavides M, Élez E, García-Alfonso P, García-Paredes B, Carrato A, Aranda E. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. Clin Colorectal Cancer 2020;19:165-77. [PMID: 32507561 DOI: 10.1016/j.clcc.2020.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Yao Y, Liu Z, Zhang H, Li J, Peng Z, Yu J, Cao B, Shen L. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. Front Pharmacol 2021;12:754858. [PMID: 34867369 DOI: 10.3389/fphar.2021.754858] [Reference Citation Analysis]
34 Jing Z, Rui Z, binglan Z. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis. J Cancer Res Clin Oncol 2019;145:2313-23. [DOI: 10.1007/s00432-019-02964-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
35 Deng Y, Li X. Fruquintinib and its use in the treatment of metastatic colorectal cancer. Future Oncol 2019;15:2571-6. [PMID: 31407939 DOI: 10.2217/fon-2018-0454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
36 Bao X, Huang Y, Xu W, Xiong G. Functions and Clinical Significance of UPF3a Expression in Human Colorectal Cancer. Cancer Manag Res 2020;12:4271-81. [PMID: 32606924 DOI: 10.2147/CMAR.S244486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cao M, Zhou M, Zhang J. Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials. J Chemother 2020;32:163-70. [PMID: 32081104 DOI: 10.1080/1120009X.2020.1728860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Chen Z, Jiang L. The clinical application of fruquintinib on colorectal cancer. Expert Review of Clinical Pharmacology 2019;12:713-21. [DOI: 10.1080/17512433.2019.1630272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
39 Li J, Cai Y, Deng Y. Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:55. [PMID: 34097129 DOI: 10.1007/s11864-021-00852-1] [Reference Citation Analysis]
40 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Zhang X, Duan R, Wang Y, Liu X, Zhang W, Zhu X, Chen Z, Shen W, He Y, Wang HQ, Huang M, Wang C, Zhang Z, Zhao X, Qiu L, Luo J, Sheng X, Guo W. FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. Ther Adv Med Oncol 2022;14:175883592110687. [DOI: 10.1177/17588359211068737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers (Basel) 2021;13:4506. [PMID: 34572729 DOI: 10.3390/cancers13184506] [Reference Citation Analysis]
43 Liu X, Guo A, Tu Y, Li W, Li L, Liu W, Ju Y, Zhou Y, Sang A, Zhu M. Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells and M1-type macrophages to protect against mouse laser-induced choroidal neovascularization. Cell Death Dis 2020;11:1016. [PMID: 33247124 DOI: 10.1038/s41419-020-03222-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
45 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Gao Z, Cao C, Bao Y, Fan Y, Chen G, Fu P. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer. Technol Cancer Res Treat 2020;19:1533033820943241. [PMID: 32914703 DOI: 10.1177/1533033820943241] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Li Y, Chen X, Li W, Ye Y, Du X, Sun S, Liu L, Zhang H. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review. Front Oncol 2021;11:684309. [PMID: 34109130 DOI: 10.3389/fonc.2021.684309] [Reference Citation Analysis]
48 Wang L, Wu J, Chen J, Dou W, Zhao Q, Han J, Liu J, Su W, Li A, Liu P, An Z, Xu C, Sun Y. Advances in reconstructing intestinal functionalities in vitro: From two/three dimensional-cell culture platforms to human intestine-on-a-chip. Talanta 2021;226:122097. [PMID: 33676654 DOI: 10.1016/j.talanta.2021.122097] [Reference Citation Analysis]
49 Procaccio L, Damuzzo V, Di Sarra F, Russi A, Todino F, Dadduzio V, Bergamo F, Prete AA, Lonardi S, Prenen H, Palozzo AC, Loupakis F. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. Drug Saf 2019;42:159-79. [PMID: 30649744 DOI: 10.1007/s40264-018-0776-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
50 Shu Y, Zheng S. Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer. Front Oncol 2021;11:688231. [PMID: 34290985 DOI: 10.3389/fonc.2021.688231] [Reference Citation Analysis]
51 Qin S, Li J, Bai Y, Deng Y, Yang L, Xu RH, Zhong H, Chen Z, Pan H, Guo W, Shu Y, Xu J, Peng C, Chen Y, Li H, Wang N, Guo X, Peng M, Fan S, Shen L. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial. Future Oncol 2021;17:1923-31. [PMID: 33563040 DOI: 10.2217/fon-2020-1215] [Reference Citation Analysis]
52 Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol 2021;17:3151-62. [PMID: 33993740 DOI: 10.2217/fon-2021-0202] [Reference Citation Analysis]
53 Lam M, Lum C, Latham S, Tipping Smith S, Prenen H, Segelov E. Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. Cancer Manag Res 2020;12:5819-30. [PMID: 32765085 DOI: 10.2147/CMAR.S213236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
54 Qureshi S, Berim L, Boland PM. Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2021;17:131-41. [DOI: 10.1007/s11888-021-00469-4] [Reference Citation Analysis]
55 Zhang Q, Wang Q, Wang X, Li J, Shen L, Peng Z. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? Int J Colorectal Dis 2020;35:295-306. [PMID: 31848739 DOI: 10.1007/s00384-019-03477-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
56 Wang RT, Zhao Y, Wang AL, Wang YT, Yin ZP, Chen K. Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study. Int J Gen Med 2021;14:5363-73. [PMID: 34522132 DOI: 10.2147/IJGM.S325545] [Reference Citation Analysis]
57 Chen J, Wang J, Lin H, Peng Y. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials. Med Sci Monit 2019;25:9179-91. [PMID: 31790382 DOI: 10.12659/MSM.918411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
58 Li J, Guo W, Bai Y, Deng Y, Yang L, Chen Z, Zhong H, Xu R, Pan H, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Xu J, Chen D, Li W, Sun S, Yu Z, Cao P, Shen L, Chen H, Wang S, Wang H, Fan S, Guo X, Wang N, Han R, Zhang B, Qin S. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. Adv Ther 2020;37:4585-98. [PMID: 32901330 DOI: 10.1007/s12325-020-01477-w] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Xu R, Wang W, Zhu B, Lin X, Ma D, Zhu L, Zhao Q, Nie Y, Cai X, Li Q, Fang W, Li H, Wang N, Chen Y, Peng C, Fang H, Shen L. Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. BMC Cancer 2020;20:131. [PMID: 32070312 DOI: 10.1186/s12885-020-6557-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ding Y, Wang J, Zhu N, Xu D, Ding K, Yuan Y. Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review. Cancer Biol Ther 2020;21:1105-8. [PMID: 33151122 DOI: 10.1080/15384047.2020.1836549] [Reference Citation Analysis]
61 Chen D, Gu K, Wang H. Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies. Cancer Manag Res 2019;11:1705-16. [PMID: 30863179 DOI: 10.2147/CMAR.S196170] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
62 Chen SM, Zhao CK, Yao LC, Wang LX, Ma YN, Meng L, Cai SQ, Liu CY, Qu LK, Jia YX, Shou CC. Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis. Acta Pharmacol Sin 2022. [PMID: 35778489 DOI: 10.1038/s41401-022-00940-4] [Reference Citation Analysis]
63 Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 2019;12:27. [PMID: 30866992 DOI: 10.1186/s13045-019-0718-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
64 Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6:201. [PMID: 34054126 DOI: 10.1038/s41392-021-00572-w] [Cited by in Crossref: 118] [Cited by in F6Publishing: 90] [Article Influence: 118.0] [Reference Citation Analysis]
65 Wu Z, Yu L, Hou J, Cui L, Huang Y, Chen Q, Sun Y, Lu W, Zhang C, Sun D, Yang D. Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9538384] [Reference Citation Analysis]
66 Qian H, Fan S, Li K, Sai Y, Su W, Chen Q, Liu Y, Li T, Wang W, Jia J, Yu C, Liu Y. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects. Clin Ther 2019;41:1537-44. [PMID: 31272709 DOI: 10.1016/j.clinthera.2019.05.014] [Reference Citation Analysis]
67 Chi Y, Shu Y, Ba Y, Bai Y, Qin B, Wang X, Xiong J, Xu N, Zhang H, Zhou J, Xu J, Cheng Y, Feng J, Hu C, Chen Y, Chen Z, Wang J, Dang C, Wang J, Wan Y, Tang Y, Wang D, Liu J, Wu M, Deng Y, Li X, Li Y, Dong J, Jiang D, Li G, Wu Q, Li J, Qi Y, Sun Y, Cai J. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703). Oncologist 2021. [PMID: 34105207 DOI: 10.1002/onco.13857] [Reference Citation Analysis]
68 Xu R, Qin S, Guo W, Bai Y, Deng Y, Yang L, Chen Z, Zhong H, Pan H, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Xu J, Chen D, Li W, Sun S, Yu Z, Cao P, Li J, Chen H, Wang J, Wang S, Wang H, Wang N, Zhang B, Han R, Su W, Guo X, Li J. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial. Future Oncol 2021;17:1339-50. [PMID: 33325251 DOI: 10.2217/fon-2020-0875] [Reference Citation Analysis]
69 Xie L, Huang H, Zheng Z, Yang Q, Wang S, Chen Y, Yu J, Cui C. MYO1B enhances colorectal cancer metastasis by promoting the F-actin rearrangement and focal adhesion assembly via RhoA/ROCK/FAK signaling. Ann Transl Med 2021;9:1543. [PMID: 34790749 DOI: 10.21037/atm-21-4702] [Reference Citation Analysis]
70 Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging Therapeutic Agents for Colorectal Cancer. Molecules 2021;26:7463. [DOI: 10.3390/molecules26247463] [Reference Citation Analysis]
71 Song Y, Wang L, Ran W, Li G, Xiao Y, Wang X, Zhang L, Xing X. Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases. Front Genet 2020;11:96. [PMID: 32161617 DOI: 10.3389/fgene.2020.00096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
74 Chen Y, Zheng X, Wu C. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Front Immunol 2021;12:792691. [PMID: 34925375 DOI: 10.3389/fimmu.2021.792691] [Reference Citation Analysis]
75 Komorowski AS, MacKay HJ, Pezo RC. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. Cancer Med 2020;9:5035-50. [PMID: 32452660 DOI: 10.1002/cam4.3095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Petrelli F, Perego G, Ghidini A, Ghidini M, Borgonovo K, Scolari C, Nozza R, Rampulla V, Costanzo A, Varricchio A, Rausa E, Pietrantonio F, Zaniboni A. A systematic review of salvage therapies in refractory metastatic colorectal cancer. Int J Colorectal Dis 2020;35:783-94. [DOI: 10.1007/s00384-020-03571-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clin Colorectal Cancer 2019;18:e117-29. [PMID: 30598357 DOI: 10.1016/j.clcc.2018.11.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
78 Wang Z, Yao Y, Mai Z, Lin W, Huang Y, Jin Y, Luo H, Zhang D, Wang F, Wang F, Chen G, Ding P, Yuan Y, Li Y, Huang J, Pan Z, Xu R. Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform. Engineering 2021;7:526-33. [DOI: 10.1016/j.eng.2020.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
79 Gou M, Qian N, Zhang Y, Yan H, Si H, Wang Z, Dai G. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. Front Oncol 2022;12:851756. [DOI: 10.3389/fonc.2022.851756] [Reference Citation Analysis]
80 Lombardi P, Marandino L, De Luca E, Zichi C, Reale ML, Pignataro D, Di Stefano RF, Ghisoni E, Mariniello A, Trevisi E, Leone G, Muratori L, La Salvia A, Sonetto C, Leone F, Aglietta M, Novello S, Scagliotti GV, Perrone F, Di Maio M. Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. Crit Rev Oncol Hematol 2020;146:102877. [PMID: 31981880 DOI: 10.1016/j.critrevonc.2020.102877] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
81 Cimino SK, Eng C. Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. J Exp Pharmacol 2020;12:475-85. [PMID: 33204182 DOI: 10.2147/JEP.S259287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Chen Y, Zhou YW, Cheng K, Li ZP, Luo DY, Qiu M, Li Q, Wang X, Shen YL, Cao D, Yang Y, Bi F, Liu JY, Gou HF. Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. Oncologist 2021;26:e1320-6. [PMID: 33830591 DOI: 10.1002/onco.13778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Mei YB, Luo SB, Ye LY, Zhang Q, Guo J, Qiu XJ, Xie SL. Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study. Drug Des Devel Ther 2019;13:2865-71. [PMID: 31616134 DOI: 10.2147/DDDT.S199362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
84 Bai M, Li ZG, Ba Y. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment. Int J Gen Med 2021;14:1041-55. [PMID: 33790633 DOI: 10.2147/IJGM.S300968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer 2021:S1533-0028(21)00071-2. [PMID: 34404621 DOI: 10.1016/j.clcc.2021.07.006] [Reference Citation Analysis]